Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Study of HBV-TCR T-cells in HBV-Related Hepatocellular Carcinoma
NCT04745403Phase 1Recruiting
- Sponsor
- Lion TCR
- Start
- May 2022
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Bone Marrow HSCs, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of liocyx-m in hepatocellular carcinoma (HCC), sponsored by Lion TCR. Primary endpoints: Safety evaluation of mRNA HBV/TCR T-cell treatment and Analysis of modifications of tumour microenvironment. Started May 2022; status: recruiting.
02
Drugs
liocyx-m
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT04745403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04745403.